MGMT and colon adenocarcinoma: In models derived from patient 172845 (colon adenocarcinoma) that shared a similar mutation profile and had the same MGMT promoter methylation status, response to temozolomide-based therapy varied based on the MGMT protein expression (Supplementary Table S2), indicating that transcriptional and post-transcriptional processes also influence response to therapy.